Net product sales consist of the following: | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended
March 31, | | (In millions) | | | | 2026 | | 2025 | EYLEA HD® | | U.S. | | $ | 468.4 | | | $ | 306.8 | | EYLEA® | | U.S. | | 473.1 | | | 736.0 | | | Total EYLEA HD and EYLEA | | U.S. | | 941.5 | | | 1,042.8 | | Libtayo® | | U.S. | | 286.1 | | | 192.5 | | Libtayo | | Rest of world | | 152.1 | | | 92.6 | | Total Libtayo | | Global | | 438.2 | | | 285.1 | | Praluent® | | U.S. | | 66.6 | | | 56.8 | | Evkeeza® | | U.S. | | 45.7 | | | 30.9 | | Lynozyfic® | | Global | | 11.2 | | | — | | Other products | | Global | | 31.3 | | | — | | | | | | $ | 1,534.5 | | | $ | 1,415.6 | |
Amounts recognized in the Company's Statements of Operations in connection with its Sanofi collaboration are as follows: | | | | | | | | | | | | | | | | | | | | | | | Statement of Operations Classification | | Three Months Ended March 31, | | (In millions) | | | 2026 | | 2025 | Regeneron's share of profits | | Collaboration revenue | | $ | 1,450.8 | | | $ | 1,018.2 | | | Reimbursement for manufacturing of commercial supplies | | Collaboration revenue | | $ | 154.3 | | | $ | 165.0 | | | Regeneron's obligation for its share of Sanofi R&D expenses, net of reimbursement of R&D expenses | | (R&D expense) | | $ | (16.7) | | | $ | (15.5) | | Reimbursement of commercialization-related expenses | | Reduction of SG&A expense | | $ | 184.1 | | | $ | 159.2 | |
Amounts recognized in the Company's Statements of Operations in connection with its Bayer collaboration are as follows: | | | | | | | | | | | | | | | | | | | | | | | Statement of Operations Classification | | Three Months Ended March 31, | | (In millions) | | | 2026 | | 2025 | Regeneron's share of profits | | Collaboration revenue | | $ | 240.0 | | | $ | 317.3 | | Reimbursement for manufacturing of commercial supplies | | Collaboration revenue | | $ | 47.3 | | | $ | 26.6 | | Reimbursement of R&D expenses, net of Regeneron's obligation for its share of Bayer R&D expenses | | Reduction of R&D expense/(R&D expense) | | $ | 1.0 | | | $ | (9.4) | |
|